Featured Research

from universities, journals, and other organizations

Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth

Date:
April 6, 2010
Source:
Helmholtz Centre for Infection Research
Summary:
The human body has developed various mechanisms, through which it can protect itself against newly-developing cancer cells. For instance, killer-cells recognize and destroy altered cells in our organs every day. Once tumors have developed, they may be inhibited in growth by messenger substances from the immune system. Scientists have now succeeded to reveal a completely unexpected function of such an immunological messenger substance in the suppression of tumors -- the molecule beta-interferon inhibits the tumor in its attempts to connect into the human blood circulatory system. Moreover, it hinders the production of growth factors that support the formation of new blood vessels. The conclusion: the tumor cannot grow.

The connection with the blood circulatory system is a significant step in the development of cancer.

Within the tissue where it is growing, the tumour develops an independent existence. With signal substances it entices white blood cells from the bone marrow into the tumour tissue. The task of these cells, usually, is to defend against infection and stimulate the healing of wounds. Within the tumour, these cells prompt new blood vessels to increase their rate of growth. Once the tumour is connected to the blood circulatory system, it is provided with nutrients for growth. It also can then disseminate its own cells into the overall blood circulatory system as well and form metastases.

Scientists at the Helmholtz Centre for Infection Research are now in the process of deciphering precisely how a messenger substance is able to inhibit this integration process into the blood circulatory system.

Messenger substances are the fine-tuning regulators of immune-cells; they activate or deactivate them, generate the production of growth factors or further messenger substances and initiate or terminate an immune reaction. One of these signal molecules is currently being used in therapy for several forms of cancer -interferon. How it works remains a mystery, so far, to scientists. Research scientist Jadwiga Jablonska from HZI has recently found a new mode of action against cancer beta-interferon a subtype of the interferons. The results surprised her: "Beta-interferon blocks the connection of the tumour into the blood vessel system by inhibiting immune cells to produce growth factors. This effect upon tumours was completely unexpected," says Jadwiga Jablonska.

The research scientist allowed skin tumours to grow in two groups of mice; the first group of mice was not able to build beta-interferon, while the second group produced the messenger substance as usual within their bodies. After a few days, the research scientist investigated the growth rate of the tumour. "In mice that cannot produce beta-interferon, the tumours were considerably larger than in the animals that did have the signal molecule in their bodies." With beta-interferon, the tumours not only grew slower -- they formed fewer and smaller metastases as well.

The reason for the inferior rate of growth was found by the research scientist to be attributable to the lack of blood circulation within the tumours. "In the presence of beta-interferon, considerably fewer blood vessels developed within the tumour," says Jadwiga Jablonska. The beta-interferon functioned through a small detour; it blocked the formation of vessel producing growth factors in cells that were enticed by the tumour to promote the connection with the blood-circulatory system. The research scientist discovered that the cells not only formed fewer growth factors, a smaller quantity of these cells found their way into the tumour, as well. "Only a negligible quantity of this messenger substance was sufficient to keep cells at bay and to inhibit growth factors, thus arresting the growth of tumours," says Jadwiga Jablonska.

"This mode of action on the part of beta-interferon had previously been unidentified," says Siegfried Weiss, leader of the working group "Molecular Immunology" at HZI. The messenger substance actually plays a significant role in viral diseases and reactions to infections. "We now are attempting to understand how the network of tumour, immune cells and messenger substance functions, in order to discover new target structures for cancer therapy," says Weiss.


Story Source:

The above story is based on materials provided by Helmholtz Centre for Infection Research. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jadwiga Jablonska, Sara Leschner, Kathrin Westphal, Stefan Lienenklaus, Siegfried Weiss. Neutrophils responsive to endogenous IFN-%u03B2 regulate tumor angiogenesis and growth in a mouse tumor model. Journal of Clinical Investigation, 2010; DOI: 10.1172/JCI37223

Cite This Page:

Helmholtz Centre for Infection Research. "Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth." ScienceDaily. ScienceDaily, 6 April 2010. <www.sciencedaily.com/releases/2010/04/100406074639.htm>.
Helmholtz Centre for Infection Research. (2010, April 6). Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/04/100406074639.htm
Helmholtz Centre for Infection Research. "Immune system's guard against cancer: How immuno-messenger substances can inhibit tumour growth." ScienceDaily. www.sciencedaily.com/releases/2010/04/100406074639.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins